- In June 2023, T2 Biosystems announced a collaboration with Vanderbilt University Medical Center to implement and assess the clinical application of the T2Bacteria Panel. This partnership aims to enhance the rapid identification of bacterial infections, which could lead to more timely and effective treatment strategies in clinical settings
- In May 2023, Sysmex Corporation launched a range of advanced products in Japan, including the clinical flow cytometry system Flow Cytometer XF-1600, the Sample Preparation System PS-10, and a selection of antibody reagents. This launch represents Sysmex's commitment to advancing diagnostic capabilities and providing healthcare professionals with the tools needed for accurate and efficient clinical analysis
- In April 2023, BioMérieux introduced BIOFIRE FIREWORKS, an innovative integrated software solution designed to enhance laboratory services associated with BIOFIRE Systems. This software aims to optimize operational efficiency while enabling laboratory professionals to make data-driven decisions, ultimately improving patient outcomes and service delivery
- In February 2023, Immunexpress successfully launched its SeptiCyte Rapid test in the U.S., designed to swiftly diagnose sepsis in patients within just one hour. This innovative point-of-care test enables clinicians to detect sepsis at an early stage, facilitating prompt intervention that can significantly improve patient outcomes. By providing rapid results, the SeptiCyte Rapid test enhances the efficiency of sepsis management in clinical settings
- In January 2023, Cytovale introduced its new IntelliSep sepsis diagnostics test, aimed specifically at patients in emergency departments experiencing symptoms of sepsis. This cutting-edge test addresses the urgent need for effective diagnostics in high-pressure environments, ensuring that clinicians can quickly assess and respond to potential sepsis cases. By enabling rapid identification, the IntelliSep test plays a crucial role in enhancing patient care in emergency medical situations
- In January 2023, PERSOWN Inc. unveiled its SMASH-H system, a real-time sepsis monitoring solution designed to tackle the growing burden of sepsis in healthcare settings. This advanced monitoring system aims to continuously track patient data, allowing for immediate detection of sepsis indicators and timely medical responses. By integrating real-time monitoring into patient care, SMASH-H seeks to reduce sepsis-related complications and improve overall patient safety
Frequently Asked Questions
The market is segmented based on Segmentation By Stages (Sepsis, Severe Sepsis, and Septic Shock), Pathogen Type (Bacteria, Fungi, and Virus), Mechanism of Action (Antibiotics, Corticosteroids, Vasoactive Agents, Analgesics, and Others), Treatment (Drugs and Surgery), Route of Administration (Oral, Intravenous, and Others), End-User (Hospitals, Homecare, Specialty Clinics, and Others), Distribution Channel (Direct, Online Pharmacy, Retailers, and Others) – Industry Trends and Forecast to 2031
.
The Global Sepsis Treatment Market size was valued at USD 15.99 USD Million in 2023.
The Global Sepsis Treatment Market is projected to grow at a CAGR of 7% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
